Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.46 |
| ▸ | HRH1 | P35367 | 7/20 | 0.41 |
| ▸ | HRH2 | P25021 | 6/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17233381 | 0.88 | KCNH2 (0.53) | KCNH2HRH3HRH1HRH2 | |
| SCHEMBL18609161 | 0.88 | KCNH2 (0.71) | KCNH2HRH3 | |
| SCHEMBL17233015 | 0.86 | KCNH2 (0.75) | KCNH2 | |
| SCHEMBL20215529 | 0.85 | KCNH2 (0.68) | KCNH2HRH3 | |
| SCHEMBL17233236 | 0.85 | KCNH2 (0.66) | KCNH2HRH3HRH1HRH2 | |
| SCHEMBL17232987 | 0.81 | KCNH2 (0.63) | KCNH2 | |
| SCHEMBL17232990 | 0.81 | KCNH2 (0.63) | KCNH2HRH3 | |
| SCHEMBL17233327 | 0.81 | KCNH2 (0.62) | KCNH2 | |
| SCHEMBL17233263 | 0.81 | KCNH2 (0.62) | KCNH2HRH3 | |
| SCHEMBL17232967 | 0.81 | KCNH2 (0.62) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3138840-B1 | THIADIAZOLIDINE DERIVATIVE AS ANTI-ENTEROVIRUS 71 | JIANGSU KANION PHARMACEUTICAL CO LTD (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-9988361-B2 | Anti-enterovirus 71 thiadiazolidine derivative | JIANGSU KANION PHARMACEUTICAL CO., LTD. (CN) | 2018-06-05 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion pharmaceutical CO. LTD (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3138840-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | Jiangsu Kanion Pharmaceutical Co., Ltd. (CN) | 2017-03-08 | — | — | EP | disclosed |
| WO-2015165340-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | 南京明德新药研发股份有限公司 | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066732-A1 | ANTI-ENTEROVIRUS 71 THIADIAZOLIDINE DERIVATIVE | EIF2AK2, GTF3C5, GTF3C1 | KCNH2 1128/4885HRH3 1155/4885HRH1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.